ML17305A671
| ML17305A671 | |
| Person / Time | |
|---|---|
| Site: | Northwest Medical Isotopes |
| Issue date: | 11/01/2017 |
| From: | Research and Test Reactors Licensing Projects Branch |
| To: | |
| Helvenston E, NRR/DLP, 415-4067 | |
| Shared Package | |
| ML17305A657 | List: |
| References | |
| Download: ML17305A671 (1) | |
Text
EXPERIMENTAL FACILITIES Northwest Medical Isotopes, LLC (NWMI or the applicant) preliminary safety analysis report (PSAR) Chapter 10.0, Experimental Facilities, states that the NWMI Radioisotope Production Facility (RPF) will not have any laboratory-scale facilities designed or used for experimental or analytical purposes that relate to the processing of irradiated materials containing special nuclear material.
The U.S. Nuclear Regulatory Commission (NRC) staff (the staff) evaluated the descriptions and discussions of the NWMI production facility as defined in Title 10 of the Code of Federal Regulations (10 CFR) Section 50.2, Definitions, in the PSAR and finds that the preliminary design of the NWMI production facility does not include experimental facilities. The staff concludes that an evaluation using the guidelines of Final Interim Staff Guidance Augmenting NUREG-1537, Part 2, Guidelines for Preparing and Reviewing Applications for the Licensing of Non-Power Reactors: Standard Review Plan and Acceptance Criteria, for Licensing Radioisotope Production Facilities and Aqueous Homogeneous Reactors (Reference 11), for experimental facilities is not required because:
(1) NWMI proposes to produce medical radioisotopes and has not described experimental, educational, or other service uses for its facility; and (2) There are no experimental facilities penetrating, located near, or that are an integral part of the facility, as described in the NWMI PSAR.